Results 271 to 280 of about 199,785 (356)
EP9158H: An Immunoinformatics-Designed mRNA Vaccine Encoding Multi-Epitope Antigens and Dual TLR Agonists for Tuberculosis Prevention. [PDF]
Zhang M +11 more
europepmc +1 more source
Linear polyglycerol is proposed as a PEG‐alternative in mRNA‐loaded lipid nanoparticles to limit activation of anti‐PEG antibodies and reduce immunogenicity. Resulting nanoparticles may provide similar gene delivery capabilities, while preventing binding of anti‐PEG antibodies compared to PEGylated counterparts.
Yara Ensminger +8 more
wiley +1 more source
mRNA Vaccine Development in the Fight Against Zoonotic Viral Diseases. [PDF]
Tan BEK, Tham SK, Poh CL.
europepmc +1 more source
Who Will Protect the Children?
Annals of the Child Neurology Society, EarlyView.
William D. Graf, Leon G. Epstein
wiley +1 more source
Poly(sarcosine) Lipid Synthesis From CO2‐Based Sarcosine‐N‐Carboxyanhydride
In this work, we optimize and scale‐up a CO2‐based synthesis of sarcosine‐N‐carboxyanhydride (Sar‐NCA) to the gram scale. The low toxicity and simplicity of the approach make it an attractive alternative to current toxic phosgene‐based approaches. The CO2‐based Sar‐NCA has sufficient purity for controlled polymerization.
Florian T. Kaps +7 more
wiley +1 more source
A single-dose mRNA vaccine protects mice from lethal Crimean-Congo hemorrhagic fever virus infection. [PDF]
Rao J +15 more
europepmc +1 more source
Machine Learning for Predictive Modeling in Nanomedicine‐Based Cancer Drug Delivery
The integration of AI/ML into nanomedicine offers a transformative approach to therapeutic design and optimization. Unlike conventional empirical methods, AI/ML models (such as classification, regression, and neural networks) enable the analysis of complex clinical and formulation datasets to predict optimal nanoparticle characteristics and therapeutic
Rohan Chand Sahu +3 more
wiley +1 more source
Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations. [PDF]
Cho Y +14 more
europepmc +1 more source

